Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial

IMPORTANCE: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Neurol
Autores principales: Stauffer, Virginia L., Dodick, David W., Zhang, Qi, Carter, Jeffrey N., Ailani, Jessica, Conley, Robert R.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143119/
https://ncbi.nlm.nih.gov/pubmed/29813147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2018.1212
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares